Skip to main content

Table 2 Subgroup analysis of the relationship between the ALI and OS

From: Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis

Subgroup factor Divided standard No. of studies HR (95% CI) P Heterogeneity
I2 (%) P het
Median age (years) < 60 5 1.59 (1.24–1.95) < 0.001 0.0 0.66
≥ 60 2 2.59 (1.56–3.63) < 0.001 0.0 0.637
Not reported 2 1.70 (1.11–2.30) < 0.001 52.9 0.145
Sample size < 170 4 2.61 (1.69–3.52) < 0.001 0.0 0.614
≥ 170 5 1.60 (1.29–1.90) < 0.001 0.0 0.749
Ethnicity Asian 6 1.80 (1.43–2.18) < 0.001 12 0.34
European 2 2.29 (0.97–3.61) NS 0.0 0.91
North American 1 1.42 (1.00–2.01) < 0.001
Pathological type NSCLC 4 1.55 (1.08–2.02) < 0.001 19.2 0.29
SCLC 2 1.64 (1.24–2.05) < 0.001 0.0 0.898
Colorectal cancer 1 2.77 (1.77–4.34) < 0.001
Head and neck squamous cell carcinoma 1 2.23 (1.12–4.55) 0.011
Diffuse large B cell lymphoma 1 2.64 (1.54–5.97) 0.019
Clinical stage Metastatic 3 1.64 (1.18–2.10) < 0.001 52.7 0.12
Non-metastatic 2 2.50 (0.78–4.21) NS 0.0 0.20
Mixed 4 1.70 (1.31–2.09) < 0.001 0.0 0.76
Treatment Surgery 3 2.37 (1.15–3.58) < 0.001 0.0 0.43
No surgery 6 1.66 (1.36–1.96) < 0.001 0.5 0.41
Cutoff of ALI < 23.2 4 1.55 (1.19–1.92) < 0.001 13.7 0.32
≥ 23.2 5 1.96 (1.47–2.44) < 0.001 0.0 0.59
  1. Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, NSCLC non-small cell lung cancer, SCLC small cell lung cancer, Mixed included patients with metastatic and non-metastatic disease, ALI advanced lung cancer inflammation index, NS not significant